https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-02-25 / Cancer Immunol Immunother 2004 Jul;53(7):633-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-02-25 / Cancer Immunol Immunother 2004 Jul;53(7):633-412004-02-25 00:00:002023-03-07 13:15:18Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-01-01 / Breast Dis 2004;20:65-71
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-01-01 / Breast Dis 2004;20:65-712004-01-01 00:00:002004-01-01 00:00:00Dendritic cell-based therapeutics for breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-01-01 / Cytotherapy 2004;6(2):154-63
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-01-01 / Cytotherapy 2004;6(2):154-632004-01-01 00:00:002019-02-15 08:50:27The immune response to breast cancer, and the case for DC immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-10-01 / Clin. Cancer Res. 2003 Oct;9(12):4376-86
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-10-01 / Clin. Cancer Res. 2003 Oct;9(12):4376-862003-10-01 00:00:002019-02-15 08:50:28Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-09-01 / Anticancer Res. 2003 Sep-Oct;23(5b):4293-303
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-09-01 / Anticancer Res. 2003 Sep-Oct;23(5b):4293-3032003-09-01 00:00:002019-02-15 08:45:51Dendritic cell-based vaccines in breast and gynaecologic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-06-15 / J. Surg. Res. 2003 Jun;112(2):189-97
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-06-15 / J. Surg. Res. 2003 Jun;112(2):189-972003-06-15 00:00:002019-02-15 08:50:29In vitro induction of tumor-specific HLA class I-restricted CD8+ cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-03-01 / Int J Hyperthermia 2003 Mar-Apr;19(2):103-18
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-03-01 / Int J Hyperthermia 2003 Mar-Apr;19(2):103-182003-03-01 00:00:002003-03-01 00:00:00The effect of whole-body hyperthermia combined with ‚metronomic‘ chemotherapy on rat mammary adenocarcinoma metastases
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-02-15 / J. Immunol. 2003 Feb;170(4):1980-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-02-15 / J. Immunol. 2003 Feb;170(4):1980-62003-02-15 00:00:002019-02-15 08:50:31Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-02-01 / Clin. Breast Cancer 2003 Feb;3 Suppl 4:S158-63
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-02-01 / Clin. Breast Cancer 2003 Feb;3 Suppl 4:S158-632003-02-01 00:00:002019-02-15 08:50:30Fusions of breast cancer and dendritic cells as a novel cancer vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-02-01 / Clin Breast Cancer 2003 Feb;3 Suppl 4:S164-72
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-02-01 / Clin Breast Cancer 2003 Feb;3 Suppl 4:S164-722003-02-01 00:00:002003-02-01 00:00:00HER2 dendritic cell vaccines
